Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Gains from Investment Securities (2016 - 2025)

Arcadia Biosciences (RKDA) has disclosed Gains from Investment Securities for 12 consecutive years, with $186504.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Gains from Investment Securities fell 14.28% year-over-year to $186504.0, compared with a TTM value of $186504.0 through Sep 2025, down 14.28%, and an annual FY2024 reading of $205475.0, up 156.59% over the prior year.
  • Gains from Investment Securities was $186504.0 for Q3 2025 at Arcadia Biosciences, up from -$2.0 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $1.5 million in Q3 2021 and bottomed at -$2.0 million in Q2 2025.
  • Average Gains from Investment Securities over 5 years is -$33201.3, with a median of $83039.0 recorded in 2023.
  • The sharpest move saw Gains from Investment Securities skyrocketed 790.79% in 2022, then crashed 58494.16% in 2025.
  • Year by year, Gains from Investment Securities stood at -$1.7 million in 2021, then soared by 107.76% to $129000.0 in 2022, then tumbled by 37.92% to $80078.0 in 2023, then grew by 7.4% to $86000.0 in 2024, then skyrocketed by 116.87% to $186504.0 in 2025.
  • Business Quant data shows Gains from Investment Securities for RKDA at $186504.0 in Q3 2025, -$2.0 million in Q2 2025, and $86000.0 in Q4 2024.